La Enhances IRES-mediated Translation of Laminin B1 During Malignant Epithelial to Mesenchymal Transition
Overview
Affiliations
The majority of transcripts that harbor an internal ribosome entry site (IRES) are involved in cancer development via corresponding proteins. A crucial event in tumor progression referred to as epithelial to mesenchymal transition (EMT) allows carcinoma cells to acquire invasive properties. The translational activation of the extracellular matrix component laminin B1 (LamB1) during EMT has been recently reported suggesting an IRES-mediated mechanism. In this study, the IRES activity of LamB1 was determined by independent bicistronic reporter assays. Strong evidences exclude an impact of cryptic promoter or splice sites on IRES-driven translation of LamB1. Furthermore, no other LamB1 mRNA species arising from alternative transcription start sites or polyadenylation signals were detected that account for its translational control. Mapping of the LamB1 5'-untranslated region (UTR) revealed the minimal LamB1 IRES motif between -293 and -1 upstream of the start codon. Notably, RNA affinity purification showed that the La protein interacts with the LamB1 IRES. This interaction and its regulation during EMT were confirmed by ribonucleoprotein immunoprecipitation. In addition, La was able to positively modulate LamB1 IRES translation. In summary, these data indicate that the LamB1 IRES is activated by binding to La which leads to translational upregulation during hepatocellular EMT.
Intricate ribosome composition and translational reprogramming in epithelial-mesenchymal transition.
Morin C, Baudin-Baillieu A, Nguyen Van Long F, Isaac C, Bidou L, Arbes H Proc Natl Acad Sci U S A. 2024; 121(50):e2408114121.
PMID: 39636864 PMC: 11648652. DOI: 10.1073/pnas.2408114121.
Breitenecker K, Heiden D, Demmer T, Weber G, Primorac A, Hedrich V Int J Mol Sci. 2024; 25(8).
PMID: 38673795 PMC: 11050718. DOI: 10.3390/ijms25084202.
Ferreira G, Thome C, Izumi C, Grassi M, Lanfredi G, Smolka M J Ovarian Res. 2023; 16(1):232.
PMID: 38031074 PMC: 10685605. DOI: 10.1186/s13048-023-01304-0.
Breitenecker K, Hedrich V, Pupp F, Chen D, Reznickova E, Ortmayr G Front Oncol. 2023; 13:1238883.
PMID: 37746265 PMC: 10514905. DOI: 10.3389/fonc.2023.1238883.
Cahill T, da Silveira W, Renaud L, Wang H, Williamson T, Chung D Sci Rep. 2023; 13(1):918.
PMID: 36650199 PMC: 9845366. DOI: 10.1038/s41598-022-26976-4.